INTERSECT ENT INC
PharmaINTERSECT ENT INC is a pharmaceutical company with 1 FDA-approved products.
INTERSECT ENT INC at a Glance
- Strong track record with 100% execution quality across 6 trials
- Fast trial execution (15 months median completion)
INTERSECT ENT INC's Key Drugs
INTERSECT ENT INC's core commercial portfolio centers on SINUVA — its most strategically important drugs approved in the last 15 years.
INTERSECT ENT INC's Recent FDA Approvals
New NDA/BLA approvals for INTERSECT ENT INC over the last two years — novel drugs only, excluding generics and label supplements.
INTERSECT ENT INC's Therapeutic Areas
Disease areas where INTERSECT ENT INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
INTERSECT ENT INC Pipeline Snapshot
Active clinical trials for INTERSECT ENT INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SINUVA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/4 completed
- • Speed: 15 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-12-08
- Latest
- 2023-01-20
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges